Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | MDM4 | O15151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439705 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL13697504 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL21474286 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL29386828 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL29400729 | 0.87 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL23373989 | 0.87 | MDM4 (0.42) | CASP3BACE1MDM4TP53MDM2 | |
| SCHEMBL31382767 | 0.85 | MDM4 (0.45) | CASP3BACE1MDM4TP53MDM2 | |
| SCHEMBL18758112 | 0.83 | CASP3 (0.46) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL31382825 | 0.83 | MDM4 (0.46) | BACE1MDM4TP53MDM2 | |
| SCHEMBL13354999 | 0.82 | CTSK (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238697-B2 | Polymeric materials and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-19 | — | — | US | disclosed |
| US-20140162943-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | ASTRAZENECA PHARMACEUTICALS, LP (US) | 2014-06-12 | — | — | US | disclosed |
| US-8642544-B2 | N-terminus conformationally constrained GLP-1 receptor agonist compounds | AMYLIN PHARMACEUTICALS, LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20120046222-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140162943-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | CASP3 1089/4885BACE1 162/4885MDM4 4816/4885 |
| US-20120046222-A1 | N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST COMPOUNDS | GLP1R, GIPR, GCGR | CASP3 1023/4885BACE1 195/4885MDM4 4808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.